Welcome

Cerecor Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drugs to make a difference in the lives of patients afflicted by neurological and psychiatric diseases. By applying our extensive knowledge and experience of neurological and psychiatric diseases and medications to treat them (“neuro-psychiatric drugs”), we have developed a systematic process to identify and advance compounds for underserved segments of common diseases and design clinical trials with the latest technologies to improve the signal-to-noise ratio and likelihood of trial success. Our process includes seeking candidates for which human proof-of-concept has been demonstrated for the compound or target and biomarkers have been identified to guide development. Learn More

News

February 20, 2015

Cerecor Bolsters Clinical Pipeline with Acquisition of Phase 2-ready Kappa Opioid Receptor Antagonist from Eli Lilly and Company

Read More

October 3, 2014

Cerecor to Present at 13th Annual BIO Investor Forum

Read More